Skip to main content
. Author manuscript; available in PMC: 2020 Aug 4.
Published in final edited form as: Pharmacogenomics. 2015 Jun 17;16(8):877–90. doi: 10.2217/pgs.15.44

Figure 3. Ara-C resistance index across different ex vivo cytotoxicity groups and in relapsed acute myeloid leukemia.

Figure 3

Ara-C resistance index across different ex vivo cytotoxicity groups and in relapsed acute myeloid leukemia: (A) RI across different ex vivo cytotoxicity groups based on IC50 obtained from MTT assay. (B) RI in low AUC and high AUC groups. (C) RI in relapse patients compared with ex vivo resistant, intermediate and sensitive patients at diagnosis. (D) RI in relapse patients compared with low AUC and high AUC groups at diagnosis. Lines represent median values for RI in each group. Statistical significance was measured using nonparametric Kruskal–Wallis or Mann–Whitney test.

AUC: Area under the survival curve; RI: Resistance index.